John Davis
Writer
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Davis
Boehringer Ingelheim Boosts COVID-19 Efforts As Jardiance Continues To Impress
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Exscientia Links With Scripp Research’s Calibr To Apply AI To COVID-19
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.